XML 21 R11.htm IDEA: XBRL DOCUMENT
v3.23.2

Accounts Payable | 6 Months Ended
--- | ---
Jun. 30, 2023
Payables and Accruals [Abstract] |
Accounts Payable | Note 4 – Accounts Payable Accounts payable consisted of the following: Schedule of Accounts Payable
|  | June 30, 2023 |  |  | December 31, 2022 |
|  | (Unaudited) |  |  |  |
Accounts payable to a third-party manufacturer |  | $ | 2,910 |  |  | $ | 2,283 |
Other accounts payable |  |  | 591 |  |  |  | 857 |
Total accounts payable |  | $ | 3,501 |  |  | $ | 3,140 |
The Company relies on a third-party contract manufacturing operation to produce and/or test our compounds used in our potential product candidates. In October 2020, the Company entered into a Master Services Agreement with a third-party product manufacturer to perform biologic development and manufacturing services on behalf of the Company. Associated with this, the Company has subsequently executed a number of Statements of Work for the research and development of products for use in clinical trials. On August 24, 2022, existing agreements with the third-party product manufacturer were amended. As part of the amendment, the third-party manufacturer agreed that services to be rendered in future periods, will be paid or settled at the Company’s discretion, in a combination of cash and issuance of the Company’s common stock. The amendment also eliminated future financial commitments of the Company. The outstanding balance payable to the third-party product manufacturer totaled $2.9 million and $2.3 million at June 30, 2023 and December 31, 2022, respectively. The Company recorded $2.1 million and $3.7 million in research and development expenses to account for services rendered by the third-party product manufacturer for the three months and six months ended June 30, 2023, as compared to $1.1 million and $3.2 million for the same comparable periods in 2022. In addition, the Company paid cash of $1.1 million and issued 1.3 million shares of its common stock with a fair value of $591 in settlement of accounts payable of $1.1 million, which resulted in a gain of on settlement of $547, during the six months ended June 30, 2023. The outstanding accounts payable balance due to the third-party product manufacturer totaled $2.9 million and $2.3 million as of June 30, 2023 and December 31, 2022, respectively.

X
- Definition The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a),20,24) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration